PL37
PL37 (Debio-0827) is an orally active, blood-brain barrier permeable dual enkephalinase inhibitor. PL37 inhibits aminopeptidase N, neprilysin, and metalloproteases, thereby blocking the degradation of endogenous enkephalins, elevating enkephalin levels, and activating peripheral μ- and δ-opioid receptors. PL37 induces mitochondrial dysfunction, mitophagy, and apoptosis, inhibits endothelial cell proliferation, migration, invasion, and tube formation, and suppresses hemangioma tumor growth and angiogenesis. PL37 can be used in research related to peripheral neuropathic pain, osteosarcoma-induced hyperalgesia, painful diabetic neuropathy, migraine, bone cancer pain, neuroinflammatory pain, and infantile hemangioma.
For research use only. We do not sell to patients.
- CAS No.: 935481-06-4
- Formula: C22H34N2O6S3
- Molecular Weight:518.71
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Opioid Receptor Isoforms
More
Biological Activity
Description
|
aminopeptidase N |
δ Opioid Receptor/DOR |
μ Opioid Receptor/MOR |
enkephalinase |
In Vitro
PL37 (Debio-0827) (100.6-116.7 μM; 24-96 h) potently inhibits the proliferation of HUVECs (IC50 = 100.6 μM) and HemECs (IC50 = 116.7 μM) in dose- and time-dependent manners[9].
PL37 (70 μM; 12-24 h) potently inhibits the migration of HUVECs and HemECs, resulting in <10% wound closure in HUVECs at 24 h[9].
PL37 (100 μM; 24 h) potently inhibits the invasive ability of HUVECs and HemECs, reducing the number of cells that penetrate the Matrigel membrane[9].
PL37 (100 μM; 24 h) potently induces apoptosis in HUVECs and HemECs[9].
PL37 (100 μM; 3-9 h) potently disrupts tubular network assembly in HUVECs and HemECs, inhibiting both branch point formation and capillary length in HUVECs and branch point formation in HemECs[9].
PL37 (100 μM; 24 h) induces marked mitochondrial fragmentation and structural disorganization in HUVECs and HemECs, significantly reducing mitochondrial aspect ratios compared to control and Propranolol (HY-B0573B)-treated cells[9].
PL37 (100 μM; 24 h) potently induces mitochondrial membrane potential collapse in HUVECs and HemECs, resulting in a significantly lower red/green fluorescence ratio than control and propranolol-treated cells[9].
PL37 (100 μM; 24 h) potently induces excessive mitochondrial ROS production in HUVECs and HemECs[9].
PL37 (100 μM; 24 h) induces severe mitochondrial ultrastructural damage and activates mitophagy in HUVECs and HemECs, as evidenced by swollen mitochondria, disorganized cristae, and increased mitophagosomes[9].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human umbilical vein endothelial cells (HUVECs), hemangioma-derived endothelial cells (HemECs)
-
Concentration:100.6 μM (HUVEC IC50); 116.7 μM (HemEC IC50)
-
Incubation Time:24 h (dose-response); 24-96 h (time-dependent analysis)
-
Result:Potently inhibited proliferation of both cell lines, with an IC50 of 100.6 μM in HUVECs and 116.7 μM in HemECs.
Suppressed cell viability in a time-dependent manner over 24 to 96 h at IC50 concentrations, with viability dropping to ~25% in HUVECs and ~10% in HemECs by 96 h.
-
Cell Line:human umbilical vein endothelial cells (HUVECs), hemangioma-derived endothelial cells (HemECs)
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Markedly induced apoptosis in both cell lines, increasing the apoptotic rate by approximately 2-fold in HUVECs and 15-fold in HemECs compared with control groups.
Increased apoptotic rate to ~50% in HUVECs and ~32% in HemECs.
-
Cell Line:human umbilical vein endothelial cells (HUVECs), hemangioma-derived endothelial cells (HemECs)
-
Concentration:70 μM
-
Incubation Time:12-24 h post-wounding
-
Result:Markedly suppressed cell motility, with HUVECs exhibiting <10% wound closure at 24 h, compared to 50% in control and 30% in propranolol-treated groups.
Exerted corresponding inhibitory effect in HemECs.
-
Cell Line:human umbilical vein endothelial cells (HUVECs), hemangioma-derived endothelial cells (HemECs)
-
Concentration:100 μM
-
Incubation Time:24 h post-attachment
-
Result:Significantly reduced the number of cells penetrating the Matrigel membrane in both cell lines.
-
Cell Line:human umbilical vein endothelial cells (HUVECs), hemangioma-derived endothelial cells (HemECs)
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Induced more pronounced mitochondrial fragmentation and structural disorganization than propranolol.
Significantly reduced the aspect ratio of mitochondria in both HUVECs and HemECs.
In Vivo
PL37 (50-100 mg/kg; p.o.; single dose) produces short-lived (maximal at 20 minutes), dose-dependent antiallodynic and anti-hypersensitive effects against mechanical static allodynia, mechanical dynamic allodynia, and mechanical dynamic hypersensitivity in vincristine-induced neuropathic rats, with no activity on cold allodynia[1].
PL37 (100 mg/kg; p.o.; single dose) has short-lived antiallodynic and anti-hypersensitive effects against mechanical static allodynia and mechanical dynamic hypersensitivity in vincristine-induced neuropathic rats that are fully reversed by peripheral opioid receptor antagonist Naloxone-methiodide (HY-137279), confirming a peripheral opioid-mediated mechanism[1].
PL37 (50-100 mg/kg; p.o.; single dose) completely inhibits acute Isosorbide Dinitrate (HY-B1409)-induced cephalic mechanical hypersensitivity in male Sprague-Dawley rats, with median von Frey withdrawal thresholds of 6.0 g and 8.0 g, respectively, at 1 hour post-treatment[4].
PL37 (20 mg/kg; i.v.; single dose) inhibits chronic isosorbide dinitrate-induced cephalic mechanical hypersensitivity in male Sprague-Dawley rats, with a median von Frey withdrawal threshold of 4.0 g at 1 hour post-treatment, while single oral doses of 50-100 mg/kg show no effect[4].
PL37 (50-100 mg/kg; p.o.; daily; 5 days) prevents chronic and interictal isosorbide dinitrate-induced cephalic mechanical hypersensitivity in male Sprague-Dawley rats, and 100 mg/kg daily treatment reduces touch-evoked trigeminocervical complex c-Fos expression by 54.1% in laminae I-IIo[4].
PL37 (100 mg/kg; p.o.; single dose; daily; 5 days; 20 mg/kg; i.v.; single dose) has no effect on cephalic mechanical sensitivity in naive male Sprague-Dawley rats[4].
PL37 (0.25-6.25 mg/kg; p.o.; single dose) dose-dependently inhibits ISDN-induced cephalic mechanical hypersensitivity in male Sprague-Dawley rats with an ED50 of 1.1 mg/kg[5].
PL37 (68.75-275 μg; p.o.; single dose, in fixed-ratio combinations with Sumatriptan (HY-B0121B)) acts synergistically with sumatriptan to inhibit ISDN-induced cephalic mechanical hypersensitivity in male Sprague-Dawley rats, with an interaction index of 0.14[5].
PL37 (Debio-0827) (2.1-25 mg/kg; p.o.; single dose) dose-dependently inhibits osteosarcoma-induced thermal hyperalgesia in male C3H/HeJ mice, with an ED50 of 16.52 mg/kg, and produces synergistic antihyperalgesic effects when combined with A-317491 (HY-15568)[8].
PL37 (10-20 mg/kg; i.v., p.o.; single dose; 1 hour before behavioral testing or SNP injection) significantly attenuates stress-induced migraine-like behaviors and SNP-primed hypersensitivity in mice via activation of peripheral delta-opioid receptors[10].
PL37 (12.5-50 mg/kg; p.o.; single dose) dose-dependently inhibits osteosarcoma-induced thermal hyperalgesia in C3H/HeJ mice, with 25 mg/kg PL37 producing complete peripheral antihyperalgesia mediated exclusively by μ-opioid receptors, and subeffective PL37 synergistically interacts with subeffective Gabapentin (HY-A0057) to completely suppress thermal hyperalgesia[2].
PL37 (20 mg/kg; i.t.; daily; 10 days) exhibits potent anti-hemangioma activity in BALB/C-nude mice, reducing tumor volume by 79.94% and tumor weight by 83% via inhibition of angiogenesis and activation of mitochondrial-mediated apoptosis, without observable toxicity[9].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (adult male, 312.3 g weight at study start, vincristine-induced peripheral neuropathic pain model)[1]
-
Dosage:70 mg/kg
-
Administration:i.p.; single dose
-
Result:Increased the Δ-paw withdrawal threshold by 8.14 arbitrary units at 20 minutes post-administration.
Showed no significant effect on Δ-paw withdrawal threshold at 50 minutes post-administration.
Had no effect on cold allodynia scores.
-
Animal Model:Sprague-Dawley (adult male, 312.3 g weight at study start, vincristine-induced peripheral neuropathic pain model)[1]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Increased the Δ-paw withdrawal threshold by 3.4 arbitrary units at 20 minutes post-administration with 50 mg/kg, and by 14.36 arbitrary units at 20 minutes post-administration with 100 mg/kg.
Produced a 75% decrease in positive responses in smooth paint-brush test at 20 minutes post-administration with 100 mg/kg, while 50 mg/kg showed a non-significant reduction.
Produced a 37.9% decrease in positive responses in rough paint-brush test at 20 minutes post-administration with 50 mg/kg, and a 75.86% decrease with 100 mg/kg.
Had no effect on cold allodynia scores.
All significant effects returned to baseline at 50 minutes post-administration.
-
Animal Model:Sprague-Dawley (adult male, 312.3 g weight at study start, vincristine-induced peripheral neuropathic pain model)[1]
-
Dosage:100 mg/kg
-
Administration:p.o.; single dose
-
Result:Significantly increased the Δ-paw withdrawal threshold at 20 minutes post-administration when administered alone, but this effect was completely antagonized by co-administration with naloxone-methiodide.
Significantly decreased positive responses in rough paint-brush test at 20 minutes post-administration when administered alone, but this effect was completely antagonized by co-administration with naloxone-methiodide.
Effects returned to baseline at 50 minutes post-administration.
-
Animal Model:C3H/HeJ (5-6 week old, 26-33 g, male/female, intratibially inoculated with NCTC 2472 osteosarcoma cells)[2]
-
Dosage:12.5 mg/kg; 25 mg/kg; 50 mg/kg; 13.4 mg/kg (ED50, PL37 alone); 7.03 mg/kg (ED50, combination with gabapentin)
-
Administration:p.o.; single dose
-
Result:Completely suppressed osteosarcoma-induced thermal hyperalgesia at 25 mg/kg, with peak effect at 20-40 minutes post-administration and effect resolving by 60 minutes, restricted to the tumor-inoculated paw.
Prolonged withdrawal latencies in both the tumor-inoculated and contralateral paws at 50 mg/kg.
Exhibited no standalone antihyperalgesic effect at 12.5 mg/kg.
Had an ED50 of 13.4 mg/kg when administered alone.
Showed synergistic interaction with subeffective gabapentin (6.25 mg/kg, i.p.) at subeffective dose of 12.5 mg/kg, completely inhibiting osteosarcoma-induced thermal hyperalgesia.
Had an experimental ED50 of 7.03 mg/kg in combination with gabapentin, significantly lower than the theoretical additive ED50 of 12.8 mg/kg, with an interaction index of 0.55.
Had antihyperalgesic effect at 25 mg/kg completely blocked by peripheral opioid antagonist naloxone-methiodide (2 mg/kg, i.p.) and selective μ-opioid receptor antagonist cyprodime (1 mg/kg, s.c.), but not by δ-opioid receptor antagonist naltrindole (0.1 mg/kg, s.c.) or κ-opioid receptor antagonist nor-binaltorphimine (10 mg/kg, s.c.).
Had bilateral analgesic effect at 50 mg/kg only partially reduced by naloxone-methiodide.
-
Animal Model:Sprague-Dawley (male, 250-275 g, isosorbide dinitrate-induced acute cephalic mechanical hypersensitivity)[4]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Completely inhibited isosorbide dinitrate-induced acute cephalic mechanical hypersensitivity.
Reached median von Frey withdrawal thresholds of 6.0 g at 1 hour post-administration for 50 mg/kg dose.
Reached median von Frey withdrawal thresholds of 8.0 g at 1 hour post-administration for 100 mg/kg dose.
-
Animal Model:Sprague-Dawley (male, 250-275 g, isosorbide dinitrate-induced chronic cephalic mechanical hypersensitivity)[4]
-
Dosage:50 mg/kg (oral, no effect); 100 mg/kg (oral, no effect); 20 mg/kg (i.v., active)
-
Administration:p.o.; single dose; i.v.; single dose
-
Result:Failed to inhibit chronic cephalic mechanical hypersensitivity at oral doses of 50 mg/kg and 100 mg/kg.
Significantly decreased chronic cephalic mechanical hypersensitivity at i.v. dose of 20 mg/kg.
Reached median von Frey withdrawal threshold of 4.0 g at 1 hour post-administration for 20 mg/kg i.v. dose.
-
Animal Model:Sprague-Dawley (male, 250-275 g, isosorbide dinitrate-induced chronic and interictal cephalic mechanical hypersensitivity)[4]
-
Dosage:50 mg/kg; 100 mg/kg
-
Administration:p.o.; daily; 5 days
-
Result:Reduced chronic cephalic mechanical hypersensitivity after the 5th isosorbide dinitrate injection, with median von Frey withdrawal thresholds of 3.0 g for 50 mg/kg dose and 4.0 g for 100 mg/kg dose at 1 hour post-administration.
Suppressed persistent interictal cephalic mechanical hypersensitivity induced by 4 consecutive isosorbide dinitrate injections.
Decreased touch-evoked c-Fos expression in the ipsilateral trigeminocervical complex by 54.1% within laminae I-IIo at 100 mg/kg dose.
-
Animal Model:Sprague-Dawley (male, 250-275 g, naive)[4]
-
Dosage:100 mg/kg (p.o. single); 20 mg/kg (i.v. single); 100 mg/kg (p.o. daily)
-
Administration:p.o.; single dose; i.v.; single dose; p.o.; daily; 5 days
-
Result:Showed no effect on cephalic mechanical sensitivity at single oral 100 mg/kg dose.
Showed no effect on cephalic mechanical sensitivity at single i.v. 20 mg/kg dose.
Showed no effect on cephalic mechanical sensitivity at repeated daily oral 100 mg/kg dose for 5 days.
-
Animal Model:Sprague-Dawley (male, 235-275 g, migraine model induced by intraperitoneal isosorbide dinitrate injection)[5]
-
Dosage:0.25 mg/kg; 1.0 mg/kg; 1.5 mg/kg; 2.0 mg/kg; 6.25 mg/kg
-
Administration:p.o.; single dose
-
Result:Produced a dose-dependent inhibition of ISDN-induced cephalic mechanical hypersensitivity.
Showed no significant effect at 0.25 mg/kg and 1.0 mg/kg doses.
Reduced the area over the curve (AOC) of cephalic hypersensitivity by 76.3% at 1.5 mg/kg (p=0.003).
Reduced the area over the curve (AOC) of cephalic hypersensitivity by 69.3% at 2.0 mg/kg (p=0.002).
Reduced the area over the curve (AOC) of cephalic hypersensitivity by 75.1% at 6.25 mg/kg (p<0.001).
Achieved a median effective dose (ED50) of 1.1 mg/kg.
-
Animal Model:Sprague-Dawley (male, 235-275 g, migraine model induced by intraperitoneal isosorbide dinitrate injection)[5]
-
Dosage:68.75 μg (in combination with 18.75 μg sumatriptan; ED50/16 ratio); 137.5 μg (in combination with 37.5 μg sumatriptan; ED50/8 ratio); 275 μg (in combination with 75 μg sumatriptan; ED50/4 ratio)
-
Administration:p.o.; single dose
-
Result:Produced a dose-dependent inhibition of ISDN-induced cephalic mechanical hypersensitivity when administered in fixed-ratio combinations with sumatriptan.
Reduced the area over the curve (AOC) of cephalic hypersensitivity by 35.5% at the ED50/16 ratio (p=0.039).
Reduced the area over the curve (AOC) of cephalic hypersensitivity by 77.4% at the ED50/8 ratio (p<0.004).
Reduced the area over the curve (AOC) of cephalic hypersensitivity by 98.4% at the ED50/4 ratio (p<0.001).
Achieved an experimental ED50 of 0.10 mg/kg for the combination, which was significantly lower than the theoretical additive ED50 of 0.71 mg/kg.
Resulted in an interaction index of 0.14.
Confirmed significant synergistic effects via isobolographic analysis.
-
Animal Model:C3H/HeJ (5- to 6-week-old male; bone cancer pain model via intratibial inoculation of NCTC 2472 fibrosarcoma cells)[8]
-
Dosage:2.1 mg/kg (1/8 of ED50); 2.36 mg/kg (1/7 of ED50); 2.75 mg/kg (1/6 of ED50); 4.13 mg/kg (1/4 of ED50); 12.5 mg/kg; 18.7 mg/kg; 25 mg/kg; 2.51 mg/kg (combination ED50)
-
Administration:p.o.; single dose
-
Result:Completely inhibited osteosarcoma-induced thermal hyperalgesia at 25 mg/kg.
Dose-dependently attenuated thermal hyperalgesia at 12.5, 18.7, and 25 mg/kg.
Achieved an ED50 of 16.52 mg/kg for oral administration.
Produced synergistic antihyperalgesic effects when coadministered with fixed ratios of A-317491, with an experimental combination ED50 of 2.51 mg/kg (significantly lower than the theoretical additive ED50 of 8.32 mg/kg) and an interaction index of 0.284.
Achieved complete antihyperalgesia with the 1/6 ED50 ratio combination.
-
Animal Model:BALB/C-nude (female, 6 weeks old, ~20 g, subcutaneous injection of 2.5 × 106 HemEC cells suspended in 100 μL Matrigel into dorsal region)[9]
-
Dosage:20 mg/kg
-
Administration:i.t.; daily; 10 days
-
Result:Reduced tumor volume by 79.94%.
Reduced tumor weight by 83%.
Suppressed microvessel formation.
Markedly suppressed VEGF and MMP9 expression.
Elevated levels of Caspase-3 and cytochrome c.
Caused no significant changes in organ structure or mouse body weight.
-
Animal Model:ICR mice (6- to 8-week-old, male and female, 25 to 34 g; repetitive restraint stress-induced migraine model)[10]
-
Dosage:10 mg/kg (i.v.); 20 mg/kg (p.o.)
-
Administration:i.v.; single dose; 1 hour before behavioral testing or SNP injection; p.o.; single dose; 1 hour before behavioral testing or SNP injection
-
Result:Significantly increased periorbital withdrawal thresholds and reduced facial grimace scores in male and female mice compared to vehicle on day 2 post-stress.
Significantly increased periorbital withdrawal thresholds at 1 and 3 hours post-administration in males and females, and at 5 hours post-administration in males only; reduced grimace scores at 1, 3, and 5 hours post-administration in both sexes (10 mg/kg i.v.).
Significantly increased facial withdrawal thresholds at 1 and 3 hours after SNP injection in male and female mice on day 14 post-stress.
Had effects blocked by delta-opioid receptor antagonist naltrindole (0.1 mg/kg) and peripherally restricted opioid receptor antagonist naloxone methiodide (5 mg/kg), but not by mu-opioid receptor antagonist CTAP (1 mg/kg).
Chemical Information
-
CAS No. 935481-06-4
-
Molecular Weight 518.71
-
Formula C22H34N2O6S3
-
SMILES
CSCC[C@H](N)CSSC[C@@H](CC1=CC=CC=C1)C(NCC(OC(C)OC(OCC)=O)=O)=O
-
Synonyms
Debio-0827
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Mitophagy Solutions
Mitophagy is the selective autophagic degradation of mitochondria and functions as a mitochondrial quality-control pathway that removes damaged, depolarized, excess, or developmentally programmed mitochondria. The pathway links mitochondrial damage recognition, autophagosome recruitment, lysosomal delivery, and mitochondrial turnover to phenotypes such as mitochondrial homeostasis, oxidative-stress control, metabolic remodeling, differentiation, and neurodegeneration-related mitochondrial fidelity. The best-characterized damage-induced pathway is the PINK1-Parkin axis. Parkin is recruited selectively to impaired mitochondria and promotes their autophagic elimination, while mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, recruits Parkin, and activates Parkin-dependent mitophagy. PINK1 also phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity, and PINK1-driven ubiquitin phosphorylation creates a feed-forward signal for recruiting autophagy machi
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Thibault K, et al. Antinociceptive and anti-allodynic effects of oral PL37, a complete inhibitor of enkephalin-catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine. European journal of pharmacology. 2008 Dec 14;600(1-3):71-7. [Content Brief]
[2]. Menéndez L, et al. Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin. European journal of pharmacology. 2008 Oct 31;596(1-3):50-5. [Content Brief]
[3]. Tesfaye S, et al. PL37: a new hope in the treatment of painful diabetic neuropathy?. Pain management. 2016 Apr;6(2):129-32. [Content Brief]
[4]. Descheemaeker A, et al. Dual enkephalinase inhibitor PL37 as a potential novel treatment of migraine: evidence from a rat model. Brain : a journal of neurology. 2022 Aug 27;145(8):2664-2670. [Content Brief]
[5]. Rossignol J, et al. Synergistic effect of combining dual enkephalinase inhibitor PL37 and sumatriptan in a preclinical model of migraine. Headache. 2024 Mar;64(3):243-252. [Content Brief]
[6]. Ashina M. Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine. Brain. 2022 Aug 27;145(8):2619-2620. [Content Brief]
[8]. González-Rodríguez S, et al. Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors. Neuroscience letters. 2009 Nov 20;465(3):285-9. [Content Brief]
[9]. Zhang M, et al. Discovery of a mitochondria-targeted propranolol conjugate PL37 that induces mitophagy for potent anti-hemangioma activity. Bioorganic & medicinal chemistry. 2026 Oct;141:118750. [Content Brief]
[10]. Mei HR, et al. Efficacy of dual enkephalinase inhibition in a preclinical migraine model is mediated by activation of peripheral delta opioid receptors. Headache. 2023 May;63(5):621-633. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)